Advertisement
Canada markets open in 8 hours 32 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7324
    +0.0001 (+0.01%)
     

  • CRUDE OIL

    83.85
    +0.28 (+0.34%)
     

  • Bitcoin CAD

    87,683.20
    -141.02 (-0.16%)
     

  • CMC Crypto 200

    1,387.54
    +4.97 (+0.36%)
     

  • GOLD FUTURES

    2,347.80
    +5.30 (+0.23%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,771.00
    +203.50 (+1.16%)
     

  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    38,022.36
    +393.88 (+1.05%)
     

  • CAD/EUR

    0.6828
    +0.0007 (+0.10%)
     

Affimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022

Affimed N.V.
·2 min read
Affimed N.V.
Affimed N.V.

HEIDELBERG, Germany, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter 2022 results and corporate update on Thursday, August 11, 2022. The Company will host a conference call at 8:30 a.m. Eastern Daylight Time.

The conference call will be available via phone and webcast. To access the call, please dial +1 (866) 374-5140 for U.S. callers, or +1 (404) 400-0571 for international callers, and use PIN : 54780189# approximately 15 minutes prior to the call. To access the live audio webcast of the conference call please visit the “Investors” section of the Company’s website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. A replay of the call will be archived on Affimed’s website for 30 days after the call.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.

Investor Relations Contact
Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102